Thirty-three isolates of Legionella pneumophila, all except one of which were clinical isolates, were tested against 20 antimicrobial agents by using an agar dilution technique. Erythromycin, rifampin, and rosaramycin were the most active agents tested. Aminoglycosides, chloramphenicol, and cefoxitin also inhibited the organisms at low concentrations. Other agents, including moxalactam, cefoperazone, and cephalosporins, exhibited moderate to little activity. Tetracycline, doxycycline, and minocycline were apparently inactivated by charcoal-yeast extract medium. There was slight inoculum dependence noted with most of the antimicrobials tested, particularly the /3-lactam agents. There was no consistent difference in susceptibility between Center for Disease Control-supplied stock strains and recent clinical isolates, but there were marked differences with some agents. Susceptibility testing needs to be standardized in view of the influence of inoculum size, strain variation, and the medium used.
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Susceptibility testing of Legionella pneumophila, the etiological agent of Legionnaires disease, has been previously reported only with small numbers of isolates (8, 9, 12, 14, 16, 17) and not with charcoal-yeast extract (CYE) agar, which has become the standard medium for L. pneumophila (6) . In addition, most strains tested have been passaged multiple times after isolation on media which do not optimally support their growth. Because of the availability of a large number of clinical isolates, which were almost entirely recently isolated and had not been passaged multiple times on nonoptimal media, susceptibility testing was performed with 20 antimicrobial agents; these include some new agents, e.g., moxalactam and cefoperazone, which have not been reported in previous studies. Inoculation of plates. The bacterial suspensions were plated onto the agar plates, using a Steers replicator (15) , within 20 min of preparation of the inocula. Antibiotic-free plates were inoculated before and after inoculation of each antibiotic-containing plate set.
MATERLALS AND METHODS
Incubation and reading of plates. All plates were incubated at 35°C in 2.5% CO2 and 65% relative humidity. The E. coli and S. aureus control tests were read and recorded at 24, 72, and 96 h. The L. pneumophila strains were read at 72 and 96 h. Less than 5 CFU per spot was read as no growth. If a strain did not grow in a confluent spot on the antibiotic-free plate, no results are reported for the antibiotic-containing plates.
Statistical analysis of differences between minimal inhibitory concentrations (MICs) was performed by using Student's t test (1 Tables  2 and 3 , in terms of both strain differences and inoculum effect. Values are not shown for the tetracycline drugs because of the possibility of their inactivation by CYE medium.
Significant differences between the MICs of the stock and clinical strains were noted with the larger inoculum size with all aminoglycosides, erythromycin, trimethoprim, cefoxitin, and cefoperazone (Table 2 ). Only testing of erythromycin and chloramphenicol at the lower inoculum size led to significant differences; conclusions regarding this effect with aminoglycosides with this inoculum cannot be made because of poor growth of clinical strains on their respective growth control plates. These differences were not always in the same direction; in some cases the MICs of the stock strains for a given drug were higher than those of the clinical strains, and in some cases they were lower.
There was a significant effect of variation of inoculum size between the same strains for all drugs except netilmicin, rosaramicin, and rifampin (Table 3 ). The differences were unidirectional, i.e., the MICs with the higher inoculum were always greater than or equal to those of the lower inoculum. Some variability was noted in that differences were not always significant for (9) . Some of the variation can also be explained by the relatively few strains tested by other investigators. All prior isolates tested by them had also been passaged multiple times. Our data concerning the differ-33  26  33  28  32  25  33  25  33  27  33  28  33  31  33  26  33  25  26  5  26  6  25  6  33  32  33  33  33  32  33  28  33  11  33  14  33  15   Rifampin   33  33 VOL. 18, 1980 on October 25, 2017 by guest http://aac.asm.org/ Downloaded from pathogenesis and host defense mechanisms.
Since there is also tremendous variability with different types of media and inoculum size, this needs to be standardized. There appears to be limited correlation between these in vitro susceptibility data and the efficacy of the drugs in the treatment of Legionnaires disease as reported by Kirby et al. (11) . Although cefoxitin seems to inhibit 100% of the strains tested at 2.0,ug/ml, we observed several therapeutic failures with cefoxitin in the treatment of Legionnaires disease (11) and in some more recently treated patients (R.D. Meyer, P.H. Edelstein, and S.M. Finegold, unpublished data).
